What to Expect When Mylan Reports Tuesday

By Chris Lange Updated Jan 30, 9:07PM EST · Published May 6, 11:05AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

What to Expect When Mylan Reports Tuesday — © mylan.com

Mylan N.V. (NASDAQ: MYL) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus forecast calls for $0.79 in earnings per share (EPS) and $2.7 billion in revenue. The same period of last year reportedly had EPS of $0.96 on $2.68 billion in revenue.

This past quarter, Mylan obtained approval to market its generic inhaler in three strengths. The Advair Diskus is marketed by GlaxoSmithKline PLC (NYSE: GSK | GSK Price Prediction), and this is far from being a small drug. Advair sales had been declining over time to about $3.1 billion globally in 2017, but the sales were over $5 billion in 2013. The website Statista showed that U.S. Advair sales were $1.6 billion in 2017.

Chronic lung diseases are serious issues for America and elsewhere. In the United States alone, over 26 million people are known to have asthma, and about 7 million of them are children. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it hard to breathe and may become worse over time, and sadly there is no cure.

[nativounit]

COPD can become debilitating and fatal over time. According to the American Lung Association, COPD is the third leading cause of death in the United States and more than 11 million people have been diagnosed with COPD. Sadly, the group warned that millions more may have the disease without even knowing it.

Excluding Monday’s move, Mylan had underperformed the broad markets, with its stock up about 2% year to date. In the past 52 weeks, the stock was actually up 24%.

A few analysts weighed in on Mylan ahead of the report:

Cantor Fitzgerald has a Hold rating.
Argus has a Buy rating with $32 price target
SunTrust has a Buy rating and a $35 price target.
UBS has a Neutral rating with a $31 price target.
Credit Suisse has a Buy rating and a $37 target.

Shares of Mylan were last seen down less than 1% at $27.85, in a 52-week range of $26.00 to $42.50. The consensus price target is $35.94.

[recirclink id=545567]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.